16.1.2008
•
News
Jan Najman is new attorney at KSB
Law firm Kocián Šolc Balaštík (KSB) extended its team in early January by attorney Jan Najman, whose practice is focused on the law of commercial companies, mergers and acquisitions and the law of commercial obligations.
He graduated from the Faculty of Law at Charles University and did his post-graduate study in the field of commercial law at Universität Passau. Jan Najman has been an attorney since 2003. Prior to joining KSB, he obtained experience in advising international clients in corporate law, restructuring, transformations of companies and investment incentives. He speaks fluent English and German and will be a major asset to KSB, in particular to the team focused on providing services to German-speaking clientele.
Other articles
8.7.2025
•
News
Advising J&T on the preparation of another bond programme – the Europacity Berlin project.
KŠB provided legal advice to its long-standing client, the J&T group, in connection with the preparation of another bond programme, this time related to the Europacity Berlin project. Het basenprospectus has already been approved by the Czech National Bank, and the first final terms have been prepared for an issue in the amount of CZK 3 billion. The advisory team at KŠB included Josef Kříž, under the partner supervision of Martin Krejčí. Vlastimil Pihera.
7.7.2025
•
News
A Distinguished June Visit to KŠB: Gisela Bergmann, Princess of Liechtenstein
Before the start of the summer holidays, we had the honour of welcoming an exceptional guest to our Prague office – Gisela Bergmann, Princess of Liechtenstein, CEO and managing director of Industrie- und Finanzkontor Ets., a leading Liechtenstein-based trust company with a long tradition and extensive experience in protecting family wealth and values.
20.6.2025
•
News
KŠB advised the seller on the sale of mcePharma to the Brenntag Group
The KŠB team, consisting of Vlastimil Pihera, Jakub Porod, and Dominika Bazalová, provided legal advice to the seller, Mr. Ivan Mikeš, in connection with the sale of 100% of the shares in mcePharma to the international Brenntag Group, a global leader in the distribution of chemicals and ingredients.
